Dianne Pulte1, Adam Gondos, Hermann Brenner. 1. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany.
Abstract
BACKGROUND: Advances in the treatment of childhood hematologic malignancies have led to improvements in survival for several of these conditions during the past few decades, but most population-based survival data available to date refer only to patients diagnosed up to the mid-1990s. METHODS: We used period analysis to assess trends in 5- and 10-year survival in US patients younger than 15 years of age at diagnosis with four hematologic malignancies--acute lymphoblastic leukemia, acute non-lymphoblastic leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma--over three recent 5-year intervals, 1990-1994, 1995-1999, and 2000-2004, using data on a total of 6957 patients from the Surveillance, Epidemiology, and End Results database. Expected survival for 2005-2009 was estimated by modeling from trends in the preceding intervals. RESULTS: Major improvements in 5- and 10-year relative survival between 1990-1994 and 2000-2004 were seen for acute lymphoblastic leukemia (from 80.2% to 87.5% and from 73.4% to 83.8%, respectively), acute non-lymphoblastic leukemia (from 41.9% to 59.9% and from 38.7% to 59.1%, respectively), and non-Hodgkin lymphoma (from 76.6% to 87.7% and from 73.0% to 86.9%, respectively). For those diagnosed with Hodgkin lymphoma, 5- and 10-year survival rates for the 1990-1994 period were 96.1% and 94.4%, respectively, and these rates did not change substantially in the later time periods. Projected 10-year survival rates for children diagnosed in the 2005-2009 period were 88.0% for acute lymphoblastic leukemia, 63.9% for acute non-lymphoblastic leukemia, 90.6% for non-Hodgkin lymphoma, and 94.3% for Hodgkin lymphoma. CONCLUSIONS: Application of period analysis to a population-based study of childhood hematologic malignancies reveals ongoing increases in survival for three of the four common childhood hematologic malignancies.
BACKGROUND: Advances in the treatment of childhood hematologic malignancies have led to improvements in survival for several of these conditions during the past few decades, but most population-based survival data available to date refer only to patients diagnosed up to the mid-1990s. METHODS: We used period analysis to assess trends in 5- and 10-year survival in US patients younger than 15 years of age at diagnosis with four hematologic malignancies--acute lymphoblastic leukemia, acute non-lymphoblastic leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma--over three recent 5-year intervals, 1990-1994, 1995-1999, and 2000-2004, using data on a total of 6957 patients from the Surveillance, Epidemiology, and End Results database. Expected survival for 2005-2009 was estimated by modeling from trends in the preceding intervals. RESULTS: Major improvements in 5- and 10-year relative survival between 1990-1994 and 2000-2004 were seen for acute lymphoblastic leukemia (from 80.2% to 87.5% and from 73.4% to 83.8%, respectively), acute non-lymphoblastic leukemia (from 41.9% to 59.9% and from 38.7% to 59.1%, respectively), and non-Hodgkin lymphoma (from 76.6% to 87.7% and from 73.0% to 86.9%, respectively). For those diagnosed with Hodgkin lymphoma, 5- and 10-year survival rates for the 1990-1994 period were 96.1% and 94.4%, respectively, and these rates did not change substantially in the later time periods. Projected 10-year survival rates for children diagnosed in the 2005-2009 period were 88.0% for acute lymphoblastic leukemia, 63.9% for acute non-lymphoblastic leukemia, 90.6% for non-Hodgkin lymphoma, and 94.3% for Hodgkin lymphoma. CONCLUSIONS: Application of period analysis to a population-based study of childhood hematologic malignancies reveals ongoing increases in survival for three of the four common childhood hematologic malignancies.
Authors: Cassandra D Josephson; Suzanne Granger; Susan F Assmann; Marta-Inés Castillejo; Ronald G Strauss; Sherrill J Slichter; Marie E Steiner; Janna M Journeycake; Courtney D Thornburg; James Bussel; Eric F Grabowski; Ellis J Neufeld; William Savage; Steven R Sloan Journal: Blood Date: 2012-04-26 Impact factor: 22.113
Authors: R Marcos-Gragera; M Solans; J Galceran; R Fernández-Delgado; A Fernández-Teijeiro; A Mateos; J R Quirós-Garcia; N Fuster-Camarena; V De Castro; M J Sánchez; P Franch; M D Chirlaque; E Ardanaz; C Martos; D Salmerón; R Peris-Bonet Journal: Clin Transl Oncol Date: 2018-04-05 Impact factor: 3.405
Authors: Michael L Rinke; Allen R Chen; David G Bundy; Elizabeth Colantuoni; Lisa Fratino; Kim M Drucis; Stephanie Y Panton; Michelle Kokoszka; Alicia P Budd; Aaron M Milstone; Marlene R Miller Journal: Pediatrics Date: 2012-09-03 Impact factor: 7.124
Authors: Fang Fang Zhang; Michael J Kelly; Edward Saltzman; Aviva Must; Susan B Roberts; Susan K Parsons Journal: Pediatrics Date: 2014-02-17 Impact factor: 7.124
Authors: Alan S Wayne; Robert J Kreitman; Harry W Findley; Glen Lew; Cynthia Delbrook; Seth M Steinberg; Maryalice Stetler-Stevenson; David J Fitzgerald; Ira Pastan Journal: Clin Cancer Res Date: 2010-03-09 Impact factor: 12.531
Authors: Michael G Brandel; Ali A Alattar; Brian R Hirshman; Xuezhi Dong; Kate T Carroll; Mir Amaan Ali; Bob S Carter; Clark C Chen Journal: J Neurooncol Date: 2017-04-24 Impact factor: 4.130